A Phase I Study of Oral ILX23-7553 [RO 237553] in Patients With Solid Tumors

Trial Profile

A Phase I Study of Oral ILX23-7553 [RO 237553] in Patients With Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 29 May 2013

At a glance

  • Drugs RO 237553 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 17 Dec 2009 Actual end date (August 2002) added as reported by ClinicalTrials.gov record.
    • 17 Dec 2009 Status changed from active, no longer recruiting to completed as reported by clinicalTrials.gov record.
    • 04 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top